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Abstract
Rationale: Poor adherence to inhaler use can be due to poor temporal and/or technique adherence. Up until now there has
been no way of reliably tracking both these factors in everyday inhaler use.
Objectives: This paper introduces a device developed to create time stamped acoustic recordings of an individual’s inhaler
use, in which empirical evidence of temporal and technique adherence in inhaler use can be monitored over time. The
correlation between clinical outcomes and adherence, as determined by this device, was compared for temporal adherence
alone and combined temporal and technique adherence.
Findings: The technology was validated by showing that the doses taken matched the number of audio recordings
(r2 = 0.94, p,0.01). To demonstrate that audio analysis of inhaler use gives objective information, in vitro studies were
performed. These showed that acoustic profiles of inhalations correlated with the peak inspiratory flow rate (r2 = 0.97, p,
0.01), and that the acoustic energy of exhalations into the inhaler was related to the amount of drug removed. Despite
training, 16% of participants exhaled into the mouthpiece after priming, in .20% of their inhaler events. Repeated training
reduced this to 7% of participants (p = 0.03). When time of use was considered, there was no evidence of a relationship
between adherence and changes in AQLQ (r2 = 0.2) or PEFR (r2 = 0.2). Combining time and technique the rate of adherence
was related to changes in AQLQ (r2 = 0.53, p = 0.01) and PEFR (r2 = 0.29, p = 0.01).
Conclusions: This study presents a novel method to objectively assess how errors in both time and technique of inhaler use
impact on clinical outcomes.
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Introduction
Inhaled medicines have the advantage of direct application of
drug to the lung with less systemic side effects. As with all
medicines, failure to achieve a response to a clinically prescribed
medicine may be the result of poor adherence. In the case of
medication delivered via inhalers poor adherence may arise from
non-use, haphazard or excessive use of medicine or poor inhaler
technique. Temporal adherence is rooted in patient perceptions of
the disease, belief in the medication, medication cost and access to
healthcare [1,2], while technique adherence is related to lack of or
failure to remember instruction [3]. Several studies have
highlighted that errors in inhaler technique may be as detrimental
as the failure to use the inhaler [4,5]. Regardless of whether it is
from not using their inhaler or using it incorrectly, the
consequences are poor clinical outcomes, wasted medications
and higher healthcare costs [6–11].
Because there are such important consequences of poor
adherence several approaches to assess inhaler adherence have
been devised. At present, the most commonly used method in
clinical trials is counting doses as read from the inhaler [12]. Other
indirect methods include biomarkers such as drug levels and
exhaled nitric oxide [13,14]. However, these methods do not give
a measure of everyday inhaler use. Electronic devices give a day-
to-day measure of inhaler use but they do not assess inhaler
technique [15]. Detection of technique errors is traditionally
carried out through a face to face process with a clinician [16,17].
However there is no way of assessing technique performance once
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Figure 1. The audio recording device, attached to the Diskus inhaler is shown in (A). In (B) the amplitude of the audio associated with an
inhaler being used is shown, in (C) the corresponding audio is shown in the frequency domain. From analysis of the audio the clear differences in the
features of each of the steps is shown. After fully opening the device, which starts electronic recording, the first critical step is the lever movement to
blister the drug. This step is characterized by a short burst of energy lasting approximately 20–30 ms with a high frequency content (,2 kHz)
preceded by a short burst of lower frequency noise (,1 kHz). Prior studies have shown that there is a difference in spectral components in the
frequency domain between inhalations and exhalations an exhalation has a sharp increase in amplitude that tapers off with time and the power of
exhalation decreases exponentially from 2 kHz to 500 Hz while the spectral power for inhalations are higher and they have a low increase in
amplitude compared to that of exhalations.18
doi:10.1371/journal.pone.0098701.g001
Table 1. Comparing Inhaler steps to INCA device Function.
Inhaler Checklist INCA Device Functionality
Impact on Technique
Adherence
1 Use thumb or finger in thumb grip to open
device until the mouthpiece appears
INCA device starts recording Critical
2 Keeps Diskus horizontal Experiments reveal that only shaking will remove drug from inhaler Non-Critical
3 Slide lever once until it clicks Blister sound identified from audio signal (‘‘drug priming’’ in figure 1B) Critical
4/5 Breathe out fully When breathing out fully
does so away from Diskus
Any exhalations in the direction of the inhaler and be observed in the
audio recording. An exhalation after the drug has been blistered is a
technique error (Figure 5A)
Critical
6 Presses lips tightly above & below
mouthpiece opening
Inhalation identified from audio signal (‘‘inhalation’’ in Figure 1B) Critical
7 Breathes IN QUICKLY, filling lungs with medicine Inhalation identified from audio signal (‘‘inhalation’’ in Figure 1B) Critical
8 Holds breath for at least 5 seconds (with or
without Diskus in mouth)
This can be detected in the audio signal (‘‘exhalation’’ in Figure 1B) Non-Critical
9 Removes Diskus before breathing normally Recording ends Critical
10 Closes Diskus by placing thumb or finger
in the thumb grip & sliding it closed
Recording ends Critical
doi:10.1371/journal.pone.0098701.t001
Validated Adherence Assessment for Inhaler Use
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the patient returns home. Hence, the limitations of all of these
methods suggest that there is a need for a technology to
longitudinally and objectively monitor both temporal and tech-
nique adherence.
The central aim of this work is to validate the hypotheses that
technique errors can have an impact on clinical outcomes for users
of inhaler medication. This was achieved by employing a device,
which for the first time can track a user’s adherence in both the
technique and temporal domain over time. Measures of adherence
over 12 weeks are determined by processing the audio files, which
are created every time the subject uses their inhaler, for evidence
of good or poor inhaler use. These values of adherence are then
correlated with changes in clinical outcomes to assess the validity
of assessing adherence in this manner.
Methods
Adherence Monitoring Device
The Inhaler Compliance Assessment (INCA) device consists of a
microphone, a battery, solid-state memory storage and a
microprocessor for recording audio. The prototype device was
attached to a Diskus inhaler Figure 1A. Recording is initiated by
opening the inhaler and finishes when the inhaler is closed. An
electronic real-time clock marks the time the recording is made
and this is stored as part of the file’s metadata. The audio is
recorded at a sampling rate of 8 kHz with an 8bit sampling
resolution, Figure 1B. An initial 49 patients used INCA Version 1.
This group of devices had a failure rate of 13%. Additionally, in
the last two weeks of the study, in these patients, 6% of device
batteries failed, however there was data available for the first two
weeks. Modification to the battery and firmware in Version 2
reduced the subsequent device failure rate to 3 of 51 devices (6%).
Each participant was recruited for three consecutive months, at
the beginning of Month1 they were given an INCA enabled
Diskus inhaler and at the end of that month they returned to the
clinic and received a replacement. During their return visit
patients had their inhaler technique assessed and corrected if
required. The audio files on the INCA device were downloaded
and processed for subsequent analysis. The protocol for this trial
and supporting CONSORT checklist are available as supporting
information; see Protocol in File S1 and CONSORT S1.
Figure 2. The amplitude and corresponding spectrogram of an individual with a weak inhalation is shown in (A). In (B) the amplitude
and corresponding spectrogram of another individual with a strong inhalation is shown. In (C) the relationship of the amplitude of inhalation to peak
inspiratory flow rate is shown, there is a strong relationship between these two variables, r2 = 0.97. In (D) the relationship of amplitude of inhalation to
drug removal is shown.
doi:10.1371/journal.pone.0098701.g002
Validated Adherence Assessment for Inhaler Use
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Classification of inhaler events
The package instructions accompanying a Diskus inhaler
describe the steps required for its correct use. Table 1 and
Figure 1B demonstrate how each of these phases can be identified
visually from a display of an acoustic recording created by the
INCA device. Visual and audio analysis was carried out using the
audio processing software Audacity, (http://audacity.sourceforge.
net).
Ethics Statement
This observational study was approved by the Beaumont
Hospital Research Ethics Committee 09/58 and the Irish
Medicines Board C10026#0 and registered with EudraCT
(number 2011-004149-42). Written informed consent was ob-
tained for all participants in the study. This study was not
registered as a clinical trial as this was considered an observational
study of the technology employed.
In vitro testing to acoustically identify the steps involved
in inhaler use
Studies showed that there was variability in the amplitude of
acoustics when individuals inhaled, Figure 2A and B. We
quantified the relationship of the acoustics of inhalation with peak
inspiratory flow rates and with drug delivery. The technical details
of these experiments are presented in ‘‘Objective measures of
acoustic profile of inhalation and exhalation’’ in File S1. The
amplitude of inhalation was closely related to the inspiratory flow
rate, R2 = 0.97, p,0.01 Figure 2C. The amplitude of inhalation
was also related to the weight of drug extracted from the inhaler,
Figure 2D. This allowed us to objectively assess if there was a
critical error in inhalation, if the median amplitude was ,
0.016AU (corresponding to a flow rate of 30 L/min) then such an
event was classed as an inhalation error.
As many files contained evidence of exhalation, after the lever
had moved to prime the inhaler, we performed studies on the
effect of exhalation on drug availability. In these it was shown that
an effort of exhalation above 1 dB, dispersed more than 50% of
the drug. Hence, if an exhalation occurred after the lever had
moved then the event was considered to be an error in inhaler
technique.
Clinical testing
A salmeterol/fluticasone Diskus inhaler was chosen for clinical
studies with the INCA device. The study inclusion and exclusion
criteria are shown in Table 2, a consort diagram is shown in
Figure 3.
Sixty-nine patients were given an INCA enabled Diskus inhaler.
The baseline characteristics of the patients are shown in Table 3.
The patient cohort consisted of 30 males (43%) and 39 (57%)
females who were prescribed either 50/250 mcg or 50/500 mcg
doses of salmeterol/flutocasone to be delivered via a Diskus
inhaler. Demographic data such as age, height and weight as well
as asthma related measurements such as Asthma Quality of Life
Questionnaire (AQLQ) and Peak Expiratory Flow Rate (PEFR)
are collected at the initial visit to the clinic. The clinical data
relating to the subjects, from month 1 to month 3 of the study, are
shown in Table 4.
All participants were recruited from Beaumont hospital and an
initial target of 50 participants was set. Initial participant
recruitment was from January 2011 until June 2012. Due to
device failures a second round of recruitment was required to meet
Figure 3. A consort diagram for the 69 patients who
participated in the study is shown.
doi:10.1371/journal.pone.0098701.g003
Table 2. Inclusion and exclusion criteria for participant recruitment.
Inclusion Exclusion
Capable of understanding and willing to provide voluntary informed
consent before any protocol specific procedures are performed
Be females of childbearing potential who are pregnant, or intend to become
pregnant, or are not using adequate contraceptive methods
Clinical diagnosis of asthma whose recent clinical condition indicates
ongoing need for combination therapy.
Have used any investigational product or device within 3 months of the enrolment
visit.
Age 18 years or older at time of consent. Have known previous sensitivity to salmeterol/fluticasone.
Capable of understanding and complying with the requirements of the
protocol, including ability to attend for all required visits.
Have a known significant (in the opinion of the investigator) concurrent medical
disease.
Able and willing to take inhaled medication.
In the opinion of the investigator suitable for use of a
salmeterol/fluticasone inhaler or already using a salmeterol/fluticasone inhaler.
doi:10.1371/journal.pone.0098701.t002
Validated Adherence Assessment for Inhaler Use
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the target number of 50, this was carried out from April 2013 until
June 2013. Any participant who experienced more than two
device failures over the course of their study period was not
included in the analysis. In June 2013 data from 51 participants
who had at least 2 months of data from INCA devices was
available for analysis.
As this was a validation study the primary endpoint was to
demonstrate that the device recordings were equivalent to the dose
counter, the current gold standard method. Exploratory secondary
aims were to quantify the prevalence of errors in technique and
compare the rates of adherence, when assessed in the time domain
alone and when technique and time of use were assessed together.
Other analysis included a comparison of adherence rates between
those subjects who demonstrated clinical improvements in AQLQ
and PEFR.
Statistical methods
The number of INCA audio recordings, which contained
acoustic evidence that the drug was dispensed, was compared to
the number of doses taken by the user, quantified by the
mechanical counter on the inhaler. The level of agreement
between these two methods of dose counting was investigated
using Pearson’s correlation coefficient and a Bland Altman plot,
figure 4A. A Bland Altman [18] plot is a difference plot used to
demonstrate the agreement between two types of measurements.
In order to determine the rate of adherence the cumulative
number of correctly taken doses was plotted against the cumulative
number of prescribed doses (2 per day) in 7 days. A regression line
was fitted to the plot and the slope of this line was calculated. This
slope is compared to that of the perfect adherence regression line,
i.e. slope = 2, to assess deviation from perfect adherence. The slope
of the line is calculated from b~r  sx

sy, where r is the
correlation between X and Y, sx is the standard deviation of the
X and sy is the standard deviation of the Y, see figures 5D & E.
Slopes of regression lines, plotting adherence rates over time, were
compared using ANCOVA to determine if the slopes of the lines
are statistically different.
Results
Device recordings and dose counter
In this study 69 patients used three separate INCA devices
attached to their salmeterol/fluticasone inhaler. From the dose
counters there were 8416 doses taken, giving an average
adherence of 89%. From the audio files downloaded from devices
that successfully recorded for the full month there were a total of
7391 inhalations. There was a close correlation between doses
taken and audio files recorded on the INCA device (Figure 4),
(R2 = 0.95 p,0.01). Manual classification was carried out by two
separate individuals for all patients. This involved visually
inspecting the audio spectrogram and listening to the audio files,
to identify each procedural step in inhaler use [19]. Inter-observer
reliability gives a kappa score of 0.7. Automation of the temporal
and technique inhaler use was then addressed by developing a
processing acoustic algorithm, which showed a sensitivity of 95%,
specificity of 94% and an accuracy of 89% in detecting inhalations
and drug priming compared to manual classification [20].
Adherence in the technique domain
The frequency of all errors and individual errors are presented
in Figure 6. In total 599 (8%) of total inhaler events (n = 7391)
were classed as containing at least one technique error. Blowing
into the device prior to an inhalation was the most common
technique error observed in this study. A number of other errors
were detected, such as breathing in and straight out Figure 6B or
moving the lever twice, Figure 6C or taking 2 doses one after
another Figure 6D. These were infrequent errors and so were
classified as ‘‘inadequate technique’’. Of the 8 (17%) subjects from
month 1 who had more than 20% technique errors, 6 reduced
their errors to less than 10% in subsequent months, after 3
consecutive episodes of training. On the other hand three patients
did not reduce the proportion of errors observed in their recorded
audio over the course of the three months. An additional three
subjects increased their errors over the 3 months. The most
significant example was from an individual who increased errors
from 8% in month 1 to 55% in month 3. This was due to
addressing step 4 in the inhaler checklist, i.e. ‘‘emptying lungs
before inhaling’’ (see Table 1). In this case the subject, who was not
completing this step before education, was now exhaling but into
the inhaler.
Adherence in the time domain
The electronic process of recording the audio file also creates a
time log; this was used to calculate the temporal adherence. The
analysis of the recordings of the overall temporal adherence for all
doses taken by the study participants is shown in Tables S1 and S2
File S1. A graphical display of inhaler use by two different patients,
generated from the metadata from the INCA device, is shown in
Figure 5B and C.
Combined adherence
Assuming that technique errors can result in a dose of
medication not being optimally delivered to the lungs, we
combined the temporal and technique data to assess this
composite effect, see Table S1 and S2 in File S1. Figures 5 C
Table 3. Baseline details of the original study cohort; BMI =
Body Mass Index, AQLQ = Asthma Quality of Life
Questionnaire, PEFR = Peak Expiratory Flow Rate.
Mean Range Confidence Interval
Age (years) 46.78 (14.5–83) 42.74–50.81
Sex Male
Female
30 39
BMI m/kg2 28.5 (15–55) 26.48–29.98
Number of exacerbations
in past year
4.45 (0–12) 2.71–4.91
Number of episodes of
steroid use in past year
2.92 (0–12) 2.16–3.68
AQLQ score 4.06 (1.1–6.7) 3.74–4.38
PEFR (L/min) 413 (155–800) 378–447
doi:10.1371/journal.pone.0098701.t003
Table 4. Recorded average clinical measures over study
period; AQLQ = Asthma Quality of Life Questionnaire, PEFR =
Peak Expiratory Flow Rate.
Values Baseline End of study p value
AQLQ 4.06 (1.13–6.73) 5.01 (1.20–7.00) 0.0005
PEFR (L/min) 417(155–800) 428(180–700) 0.211
doi:10.1371/journal.pone.0098701.t004
Validated Adherence Assessment for Inhaler Use
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and E in particular demonstrate the effect technique errors can
have on overall adherence. A significant number of technique
errors (yellow dots) can be seen in the data for week 1. Although
the patient roughly took the recommended number of doses over
this period, the technique errors significantly affected adherence
rate reducing it from an expected rate of 2 to 0.8. It can then be
seen that technique errors improve in subsequent weeks, and
adherence rate increase to a more acceptable value, 1.6. In month
1, when considering technique errors the same as missed doses the
rate of adherence was 10% lower than when just the temporal
adherence was considered alone.
Relationship of clinical progress to adherence
Among the study participants there was an overall significant
increase in AQLQ (p,0.001) over the 12 weeks of study, see
Table 4. An exploratory analysis was performed to relate the rate
of adherence in those who achieved at least a minimum clinically
important improvement in AQLQ of 0.5 (n = 28) and those who
did not (n = 18) [21]. No statistical difference was observed
between the two groups for age or baseline PEFR, however there
was a statistical difference in the BMI’s and AQLQ scores for the
two groups (p = 0.04 and 0.02 respectively). For this analysis
temporal adherence only considers whether two doses were taken
Figure 4. A Bland Altman plot showing the relationship of the doses taken, recorded by the dose counter on the Diskus and the
number of audio files logged on the metadata of the INCA device is shown in (A). In (B) the same data is displayed as a correlation of the
doses taken to the number of audio recordings.
doi:10.1371/journal.pone.0098701.g004
Validated Adherence Assessment for Inhaler Use
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in a day. When plotting rate of inhaler use (Figure 7A) no
relationship between the rate of adherence and clinical outcomes
was observed. When data on time and technique was combined a
correlation between the AQLQ-improvers group and this
combined adherence rate was observed; with a downward trend
in adherence for the non-improving group, (p = 0.017) and an
upward trend from improvers (p = 0.02), Figure 7B. The same
analysis was carried out comparing those with improvements and
no improvements in PEFR, n= 20 and n= 28 respectively. There
was no statistical difference in the age, BMI, initial PEFR or
AQLQ scores between these two groups. No relationship between
adherence, calculated simply by time of use between improvers
and decliners, was observed however using a composite rate of
adherence showed a distinction in the trend between improvers
and non-improvers in terms of their PEFR rate, p = 0.016,
(Figure 7 C & 7D).
Discussion
This study reports a novel method to assess the use of an inhaler
by an individual. The technology involves an audio recording
device and a methodology which provides objective evidence of
inhaler use and a novel way to calculate adherence. The clinical
significance of this approach is that when both the technique of
inhaler use and the time of use are considered together this
provides a more objective relationship of the patient’s use of an
inhaler to their outcomes.
We undertook this study because there is a need to have a
technology that quantifies when and how an inhaler has been
used, since clinicians often cannot distinguish if the progression of
a condition such as asthma is influenced by adherence to therapy
or deterioration in the condition. As a means of assessing inhaler
use, audio recordings have several advantages. Electronic record-
ings are time stamped, so that the time of use can be assessed and
the technology involved in audio recording devices has become
smaller and more robust. Furthermore, audio can be analysed in
Figure 5. The decision algorithm, outlining the steps taken to analyse each recording, is shown in (A). In (B) and (C) the data from two
individuals over 90 days are shown on the X-axis, and the time of use on the Y-axis. If the sequence of events required for correct inhaler use is
performed, with sufficient energy of inhalation, then the event is displayed with a green spot. If there is a critical error, then the event is displayed
with an orange spot. In (D) and (E) the weekly rate of adherence incorporating the time and technique are shown. It should be noted that while both
users took their inhalers very regularly, the individual in (E) had poor technique in the first month, which impacted the true rate of inhaler use.
doi:10.1371/journal.pone.0098701.g005
Validated Adherence Assessment for Inhaler Use
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the time and frequency domains, meaning that objective
quantifiable features corresponding to each step of the use of the
inhaler can be identified and extracted for analysis. We initially
used human raters in the assessment of the steps of inhaler use and
then devised a method to perform the process automatically. We
compared these automated assessments with those made by
trained human assessors. The automatic signal processing method
has a high sensitivity and specificity [22]. This means that analysis
can be performed rapidly so that the information can be presented
to an individual in real time.
The traditional methods of assessing adherence with dose
counters or electronic recordings reflect when the inhaler was used
but they do not assess how it was used. In this study there was no
relationship between temporal adherence and clinical outcomes. It
was only when errors in inhaler use and time of use were
combined that a relationship between changes in adherence and
changes in outcomes was identified. This means that it is
important to know both when and how an inhaler was used.
Analysis of the audio recordings revealed some important
findings that are not easily identified by the traditional method of
direct visual assessment. Direct visual assessment simply shows that
the individual is competent in using their inhaler but cannot
guarantee that the process is followed in the individual’s home
environment. In this study all patients were fully trained and
judged to be competent in the use of their inhaler at the start of the
observation period but nonetheless 17% of patients had more than
20% errors during the initial month. This indicates that errors do
persist despite one-to-one education. It has been shown previously
Figure 6. The percentage of all recordings with an error in use is shown in (A). Before participating in the study all patients had
demonstrated that they were proficient in inhaler use, nonetheless at the end of month 1, 10% of all inhalations had a critical error. Over the next two
months there was a significant reduction in the number of errors made by the patients, (*, p,0.05). In (B) a recording of an individual taking two
doses, one after the other is shown. In (C) a recording of an individual moving the lever back twice, effectively wasting a dose. In (D) an example of a
recording where the user exhales into the mouthpiece after priming and before inhalation
doi:10.1371/journal.pone.0098701.g006
Validated Adherence Assessment for Inhaler Use
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that repeated education leads to better inhaler technique [23] and
this was also the case in this study. In fact it required three
consecutive training sessions, over 3 months, to reduce errors in
technique to ,5% of all inhaler events. In this observational study
eliminating these errors corresponded to the observed improve-
ment in asthma quality of life. The majority of patients who made
errors did not do so every time suggesting that these errors reflect
carelessness rather than poor proficiency. Despite repeated
training three patients did not improve their technique and three
actually developed errors in their inhaler technique. Hence, while
patients can be seen to be competent in using their inhaler many
persist in making mistakes, which have direct clinical impact, when
they use their inhaler outside of the training setting. Given that the
acoustic algorithm can process the audio data in real-time we can
incorporate this information into a tailored training program
based on an individual’s own technique errors. By displaying
information on rate of use along with information on clinical
symptoms and PEFR, as shown in Figure S1, we can provide an
individual with a greater insight into the relationship of inhaler use
to their own outcomes. A clinical trial is underway to assess if
providing such feedback improves clinical outcomes more than
generic inhaler training.
In vitro, studies have demonstrated a strong relationship
between the acoustics of inhalation and the inspiratory flow rate.
Devices such as the peak inspiratory flow rate meter can assess if
the patient can achieve a certain flow but they cannot assess the
day-to-day flow rate achieved by the patient. Most patients in the
study easily achieved an adequate peak inspiratory flow. However
other patients, for example those with COPD, may not achieve
adequate flow rates, which will limit the effectiveness of their
inhaler [24].
The most common error made by patients was an exhalation
into the inhaler after the lever had been deployed to activate the
drug. This error disperses the medication away from the
Figure 7. In (A) the rate of adherence by time of use for patients who improved by the minimum clinically important difference in
AQLQ are shown in red and those who did not is shown, in black. Time of inhaler use did not relate to changes in clinical status. In (B) the
adherence rate including the time and technique of use is shown. Those who had at least a minimum important clinically difference in AQLQ over the
observation period are shown in blue, while those who did not are shown in green. There was a significant relationship between the rate of
adherence and the outcomes in AQLQ when both time and technique were assessed. In (C) the rate of adherence by time of use for patients who
changes in PEFR is shown, the red line is those who had a trend of improved PEFR and those who did not is shown, in blue. In (D) the adherence rate
including the time and technique of use is shown, there was an association of the improvement in PEFR with increased inhaler use, blue and those
who did not, green.
doi:10.1371/journal.pone.0098701.g007
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mouthpiece and so reduces the quantity of drug available for
subsequent inhalation. Another component of this error is the
introduction of water vapour to the mouthpiece which can also
impact drug delivery (further details on the impact are discussed in
the accompanying second manuscript). In this study analysis of the
audio files allowed us to objectively identify when this error
occurred. For most patients this seemed to occur because they do
not recognise the importance of the instruction ‘‘exhale fully away
from the device’’. Having objective evidence from the audio
recordings ensures that these errors are identified. Development is
currently ongoing to automate the classification of inhaler events.
This will result in a very usable system for monitoring patients in a
clinical environment. Technique errors are specific to this type of
inhaler; however there are many types of inhalers available, each
with their individual potential technique errors. For example the
orientation of the diskus inhaler is often considered a potential
source of technique error. It is recommended that the inhaler is
kept horizontal during use. Preliminary experiments demonstrated
an inhaler held at 45u or 90u will only loose between 0 and 5% of
drug present in the inhaler. It is only with shaking or tapping the
inhaler when help at 90u that drug will be dislodged from this
inhaler. This study presents a successful framework for identifying
technique errors and establishing objective methods of classifica-
tion of these errors
There are several limitations to the study. Firstly, the rates of
adherence were very high, compared with other studies of
adherence in asthma [1,6,8,11,14,15]. The study was performed
in the setting of a formal research setting. In other preliminary
studies, in general practice, on hospital wards and in their own
home following exacerbations of COPD with this device, we have
shown much lower levels of adherence [25,26]. In the current
study the participants were fully aware of the purpose of the study,
which was to assess inhaler use over a period of time. Therefore,
the usual limitations of this type of study design apply; including
the Hawthorne effect, knowing that there adherence was being
assessed may well have altered the rates of adherence. The results
do indicate that despite high levels of temporal adherence many
patients had errors in technique which when they were addressed
were associated with improvements in their symptoms. Hence,
repeated training in inhaler technique has direct clinical effects.
In summary, we describe the use of audio recordings to provide
objective longitudinal evidence of inhaler use. This information
can provide an insight into the relationship between inhaler use
and an individual’s clinical course over time.
Supporting Information
File S1 This document contains the clinical protocol for
data collection, a description of the methods used to
relate acoustic properties to peak flow rate, and the
supplementary tables, Tables S1 & S2.
(DOC)
Figure S1 The figure shows an individual’s inhaler daily
use, peak flow recordings and AQLQ over a 90 day
period. The patient shows a progressive improvement in PEFR
and AQLQ over the time, during which they demonstrate
excellent adherence. The figure also shows that having achieved
optimal PEFR and AQLQ they show a more variable adherence
rate.
(TIF)
Figure S2 Experimental setup of equipment used to
extract drug from the Diskus DPI is shown.
(TIF)
Checklist S1 CONSORT Checklist.
(DOC)
Acknowledgments
The authors thank Professors Dermot Kenny (RCSI) and Pat Murray
(UCD) as well as Jeremy Towns from the Dublin Clinical Centre for
Research. The authors thank Dr. David Leather, Martijn Akveld, and Dr
Kate Knobil from GSK for providing the Diskus inhalers for this study and
Professor Peter Calverley for advice on an earlier version of this paper. The
authors also thank the research nurses in the clinical research centre RCSI
and clinical research centre UCD for all their contributions to running this
study.
Author Contributions
Conceived and designed the experiments: IK CH MSH TT RWC TA-Z.
Performed the experiments: EMH DH RWC. Analyzed the data: SD IS JS
MSH RWC. Contributed reagents/materials/analysis tools: FK JMC.
Wrote the paper: SD IS RWC RR. Clinical advisors and provided access
to patients: COR SG.
References
1. Heaney LG, Horne R (2012) Non-adherence in difficult asthma: time to take it
seriously. Thorax 67(3): 268–270
2. Horne R, Weinman J, Barber N, Elliott RA, Morgan M (2006) Concordance,
Adherence and Compliance in Medicine Taking: A conceptual map and
research priorities. National Co-ordinating Centre for NHS Service Delivery
and Organisation R&D, London, 2006.
3. Crompton GK, Barnes PJ, Broeders M, Corrigan C, Corbetta L, et al. (2006)
The need to improve inhalation technique in Europe: A report from the Aerosol
Drug Management Improvement Team. Respir Med 100: 1479–1494.
4. Price D, Bosnic-Anticevich S, Briggs A, Chrystyn H, Rand C, et al. (2013)
Inhaler competence in asthma: Common errors, barriers to use and
recommended solutions. The Inhaler Error Steering Committee, J. Respir
Med 107(1): 37–46
5. Nikander K, Turpeinen M, Pelkonen AS, Bengtsson T, Selroos O, et al. (2011)
True adherence with the Turbuhaler in young children with asthma. Arch Dis
Child 96: 168–173.
6. Murphy AC, Proeschal A, Brightling CE, Wardlaw AJ, Pavord I, et al. (2012)
The relationship between clinical outcomes and medication adherence in
difficult-to-control asthma. Thorax 67(8): 751–3.
7. Williams LK, Pladevall M, Xi H, Peterson E, Joseph C, et al. (2001)
Relationship between adherence to inhaled corticosteroids and poor outcomes
among adults with asthma. J Allergy Clin Immunol 114: 1288–1293.
8. Krishnan JA, Riekert KA, McCoy JV, Stewart DY, Schmidt S, et al. (2004)
Corticosteroid use after hospital discharge among high-risk adults with asthma.
Am J Respir Crit Care Med 1281–1285
9. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B (2000) Low-dose inhaled
corticosteroids and the prevention of death from asthma. N Engl J Med 332–336
10. Donahue JH, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, et al.
(1997) Inhaled steroids and the risk of hospitalization for asthma. JAMA 277:
887–891
11. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, et al (1996). Non-
compliance and treatment failure in children with asthma. J Allergy Clin
Immunol 98: 1051–1057
12. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, et al. (2010)
Tiotropium bromide step-up therapy for adults with uncontrolled asthma.
N Engl J Med 363(18): 1715–26.
13. Foster JM, Smith L, Usherwood T, Sawyer SM, Rand CS, et al. (2012) The
Reliability and Patient Acceptability of the SmartTrack Device: A New
Electronic Monitor and Reminder Device for Metered Dose Inhalers.
J Asthma 49(6): 657–662
14. McNicholl DM, Stevenson M, McGarvey LP, Heaney LG (2012) The utility of
fractional exhaled nitric oxide suppression in the identification of nonadherence
in difficult asthma. Am J Respir Crit Care Med 186(11): 1102–8.
15. Gamble J, Stevenson M, McClean E, Heaney LG (2011) The Prevalence of
Nonadherence in Difficult Asthma. Am J Respir Crit Care Med, 180(9): 814–
822
16. Press VG, Arora VM, Shah LM, Lewis SL, Ivy K, Chareneau J, et al. (2011).
Misuse of Respiratory inhalers in Hospitalized patients with asthma and COPD.
J Gen Intern Med 26 (6): 635–42.
Validated Adherence Assessment for Inhaler Use
PLOS ONE | www.plosone.org 10 June 2014 | Volume 9 | Issue 6 | e98701
17. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, et al. (2011) Inhaler
mishandling remains common in real life and is associated with reduced disease
control. Respiratory Medicine 105(6): 930–938
18. Altman DG, Bland JM (1983) Measurement in medicine: the analysis of method
comparison studies. The Statistician 32: 307–317
19. Alshaer H, Fernie GR, Bradley T (2011) Monitoring of breathing phases using a
bioacoustic method in healthy awake subjects. J Clin Monit Comput 25(5): 285–
94.
20. Holmes MS, D’Arcy S, Costello RW, Reilly RB (2013) Acoustic Analysis of
Inhaler Sounds From Community-Dwelling Asthmatic Patients for Automatic
Assessment of Adherence. Translational Engineering in Health and Medicine,
IEEE Journal of 2(1): p. 1–10.
21. Juniper EF, Guyatt GH, Willan A, Griffith LE (1994) Determining a minimal
important change in a disease-specific quality of life questionnaire. J Clin
Epidemiol 47: 81–87
22. Holmes MS, LeMenn M, D’Arcy S, Rapcan V, MacHale E, et al. (2012)
Automatic Identification and Accurate Temporal Detection of Inhalations in
Asthma Inhaler Recordings. 34rd Annual International IEEE EMBS Confer-
ence, San Diego, USA.
23. Takemura M, Mitsui K, Itotani R, Ishitoko M, Suzuki S, et al. (2011).
Relationships between repeated instruction on inhalation therapy, medication
adherence, and health status in chronic obstructive pulmonary disease.
Int J Chron Obstruct Pulmon Dis 6: 97–104.
24. Selroos O, Borgstro¨m L, Ingelf J (2009) Use of dry powder inhalers in acute
exacerbations of asthma and COPD. Ther Adv Respir Dis 3(2): 81–91
25. Costello RW, Holmes M, Reilly RB (2013) Assessing True Inhaler Adherence in
COPD Patients. Am J Respir Crit Care Med 187_A5234.
26. Costello RW, Reilly RB, Hughes C, McGee P, Long DA (2012) Novel Device
To Detect Errors In Adherence In Inpatients Am J Respir Crit Care Med 185.1
MeetingAbstracts.A3330
Validated Adherence Assessment for Inhaler Use
PLOS ONE | www.plosone.org 11 June 2014 | Volume 9 | Issue 6 | e98701
View publication stats
